AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Agenus Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Garo H. Armen received 3,619 shares of Agenus Inc. common stock as salary in lieu of cash for the pay period ending August 22, 2025. The shares were issued at a closing price of $4.52 on August 22, 2025, and are fully vested on issuance under the company's amended 2019 Equity Incentive plan. After the reported issuance, Dr. Armen is shown as beneficial owner of 270,930 shares directly, plus indirect holdings of 31,298 and 28,950 shares tied to his IRA accounts and other entities where he holds trustee or partnership roles.

The Form 4 reflects routine insider compensation reporting rather than an open-market purchase or sale; the filing was signed by an attorney-in-fact on August 25, 2025. Explanatory footnotes state the stock issuance was approved by the Agenus Compensation Committee and represents net salary for the stated payroll period.

Garo H. Armen ha ricevuto 3.619 azioni ordinarie di Agenus Inc. come compenso in sostituzione del pagamento in contanti per il periodo retributivo terminato il 22 agosto 2025. Le azioni sono state emesse al prezzo di chiusura di $4,52 il 22 agosto 2025 e risultano pienamente maturate al momento dell'emissione ai sensi del piano di incentivi azionari emendato del 2019 dell'azienda. Dopo l'assegnazione riportata, il dott. Armen risulta titolare beneficiario di 270.930 azioni in proprietà diretta, oltre a partecipazioni indirette di 31.298 e 28.950 azioni correlate a suoi conti IRA e ad altre entità nelle quali ricopre ruoli di fiduciario o partner.

Il modulo Form 4 descrive una comunicazione ordinaria relativa alla retribuzione di un insider e non l'acquisto o la vendita sul mercato aperto; la documentazione è stata firmata da un procuratore il 25 agosto 2025. Le note esplicative indicano che l'emissione delle azioni è stata approvata dal Compensation Committee di Agenus e rappresenta il salario netto per il periodo di paga indicato.

Garo H. Armen recibió 3.619 acciones ordinarias de Agenus Inc. como salario en lugar de efectivo por el período de pago que finalizó el 22 de agosto de 2025. Las acciones se emitieron al precio de cierre de $4.52 el 22 de agosto de 2025 y están totalmente consolidadas al emitirse conforme al plan enmendado de incentivos de capital de 2019 de la compañía. Tras la emisión informada, el Dr. Armen figura como titular beneficiario de 270.930 acciones en propiedad directa, además de participaciones indirectas de 31.298 y 28.950 acciones vinculadas a sus cuentas IRA y a otras entidades donde actúa como fiduciario o socio.

El Formulario 4 refleja un informe rutinario sobre la compensación de un insider y no una compra o venta en el mercado abierto; la presentación fue firmada por un apoderado el 25 de agosto de 2025. Las notas aclaratorias señalan que la emisión de acciones fue aprobada por el Comité de Compensación de Agenus y representa el salario neto correspondiente al período de nómina señalado.

ê°€ë¡� H. ì•„ë©˜ì€ 2025ë…� 8ì›� 22ì¼ë¡œ 마ê°ë� 급여지ê¸� 기간ì—� 대í•� 현금 대ì‹� 급여ë¡� Agenus Inc. 보통ì£� 3,619주를 받았습니ë‹�. 해당 주ì‹ì€ 2025ë…� 8ì›� 22ì� 종가 $4.52ì—� 발행ë˜ì—ˆìœ¼ë©°, 회사ì� 개정ë� 2019ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ë°œí–‰ 시ì ì—� ì „ì•¡ 권리가 확정ë˜ì—ˆìŠµë‹ˆë‹�. ë³´ê³ ë� 발행 í›� 아멘 박사ëŠ� ì§ì ‘ 소유 270,930주와 ê·¸ì˜ IRA 계좌 ë°� 그가 수íƒìž� ë˜ëŠ” 파트너로 있는 기타 법ì¸ê³� ê´€ë ¨ëœ ê°„ì ‘ 보유 31,298ì£� ë°� 28,950주를 보유í•� 것으ë¡� 나타납니ë‹�.

Form 4ëŠ� 공개시장 매수ë‚� 매ë„ê°€ 아닌 ë‚´ë¶€ìž� 보수ì—� 대í•� 통ìƒì ì¸ ë³´ê³ ìž„ì„ ë°˜ì˜í•˜ë©°, 제출 서류ëŠ� 2025ë…� 8ì›� 25ì� 대리ì¸ì� 서명했습니다. 설명 ê°ì£¼ì—는 ì£¼ì‹ ë°œí–‰ì� Agenus ë³´ìƒìœ„ì›íšŒì˜ 승ì¸ì� 받았ê³� 명시ë� 급여 기간ì—� 대í•� 순급여를 대체한다는 ë‚´ìš©ì� 기재ë˜ì–´ 있습니다.

Garo H. Armen a reçu 3 619 actions ordinaires d'Agenus Inc. en rémunération en lieu et place d'un paiement en espèces pour la période de paie se terminant le 22 août 2025. Les actions ont été émises au cours de clôture de 4,52 $ le 22 août 2025 et sont entièrement acquises à l'émission conformément au plan d'incitation en actions modifié de 2019 de la société. Après l'émission déclarée, le Dr Armen apparaît comme bénéficiaire effectif de 270 930 actions en propriété directe, ainsi que de participations indirectes de 31 298 et 28 950 actions liées à ses comptes IRA et à d'autres entités où il exerce des fonctions de fiduciaire ou de partenaire.

Le formulaire Form 4 reflète un rapport de rémunération interne de routine plutôt qu'un achat ou une vente sur le marché ouvert ; le dépôt a été signé par un mandataire le 25 août 2025. Les notes explicatives indiquent que l'émission d'actions a été approuvée par le comité de rémunération d'Agenus et représente le salaire net pour la période de paie indiquée.

Garo H. Armen erhielt 3.619 Stammaktien der Agenus Inc. als Gehaltszahlung anstelle von Bargeld für den Abrechnungszeitraum, der am 22. August 2025 endete. Die Aktien wurden zum Schlusskurs von $4,52 am 22. August 2025 ausgegeben und sind gemäß dem geänderten Equity Incentive Plan von 2019 des Unternehmens bei Ausgabe vollständig unverfallbar. Nach der gemeldeten Zuteilung wird Dr. Armen als wirtschaftlicher Eigentümer von 270.930 Aktien direkt sowie von indirekten Beständen von 31.298 und 28.950 Aktien ausgewiesen, die mit seinen IRA-Konten und anderen Gesellschaften verbunden sind, bei denen er als Treuhänder oder Partner fungiert.

Das Formular Form 4 dokumentiert eine routinemäßige Insidervergütungsmeldung und keinen Kauf oder Verkauf am offenen Markt; die Einreichung wurde am 25. August 2025 von einem Bevollmächtigten unterzeichnet. Erläuternde Fußnoten geben an, dass die Aktienausgabe vom Vergütungsausschuss von Agenus genehmigt wurde und das Nettogehalt für den genannten Abrechnungszeitraum darstellt.

Positive
  • Salary paid in stock shows alignment of executive compensation with shareholder interests
  • Shares are fully vested on issuance, avoiding future vesting uncertainty
Negative
  • None.

Insights

TL;DR: Insider received equity compensation (3,619 shares) in lieu of cash; modest change to share count, routine disclosure for payroll issuance.

The reported transaction is an issuance of 3,619 shares as salary compensation at the closing price of $4.52 on August 22, 2025. This increases the reporting person’s direct beneficial ownership to 270,930 shares. From a financial perspective, this is a non-cash compensation event that dilutes outstanding equity marginally but is primarily an internal payroll mechanism rather than a market-driven trade. The filing provides clear attribution of indirect holdings (IRAs, GRAT, partnership) which clarifies ownership structure.

TL;DR: Compensation Committee-approved stock-for-salary conversion is standard governance practice; disclosure meets Section 16 reporting requirements.

The Form 4 documents that the Compensation Committee approved payment of Dr. Armen’s salary in stock under the Amended and Restated 2019 Equity Incentive plan, and that the shares vested immediately on issuance. The filing also discloses indirect ownership via IRAs, a GRAT, and a partnership with appropriate disclaimers of pecuniary interest. This is a routine governance disclosure that enhances transparency about insider holdings and control relationships.

Garo H. Armen ha ricevuto 3.619 azioni ordinarie di Agenus Inc. come compenso in sostituzione del pagamento in contanti per il periodo retributivo terminato il 22 agosto 2025. Le azioni sono state emesse al prezzo di chiusura di $4,52 il 22 agosto 2025 e risultano pienamente maturate al momento dell'emissione ai sensi del piano di incentivi azionari emendato del 2019 dell'azienda. Dopo l'assegnazione riportata, il dott. Armen risulta titolare beneficiario di 270.930 azioni in proprietà diretta, oltre a partecipazioni indirette di 31.298 e 28.950 azioni correlate a suoi conti IRA e ad altre entità nelle quali ricopre ruoli di fiduciario o partner.

Il modulo Form 4 descrive una comunicazione ordinaria relativa alla retribuzione di un insider e non l'acquisto o la vendita sul mercato aperto; la documentazione è stata firmata da un procuratore il 25 agosto 2025. Le note esplicative indicano che l'emissione delle azioni è stata approvata dal Compensation Committee di Agenus e rappresenta il salario netto per il periodo di paga indicato.

Garo H. Armen recibió 3.619 acciones ordinarias de Agenus Inc. como salario en lugar de efectivo por el período de pago que finalizó el 22 de agosto de 2025. Las acciones se emitieron al precio de cierre de $4.52 el 22 de agosto de 2025 y están totalmente consolidadas al emitirse conforme al plan enmendado de incentivos de capital de 2019 de la compañía. Tras la emisión informada, el Dr. Armen figura como titular beneficiario de 270.930 acciones en propiedad directa, además de participaciones indirectas de 31.298 y 28.950 acciones vinculadas a sus cuentas IRA y a otras entidades donde actúa como fiduciario o socio.

El Formulario 4 refleja un informe rutinario sobre la compensación de un insider y no una compra o venta en el mercado abierto; la presentación fue firmada por un apoderado el 25 de agosto de 2025. Las notas aclaratorias señalan que la emisión de acciones fue aprobada por el Comité de Compensación de Agenus y representa el salario neto correspondiente al período de nómina señalado.

ê°€ë¡� H. ì•„ë©˜ì€ 2025ë…� 8ì›� 22ì¼ë¡œ 마ê°ë� 급여지ê¸� 기간ì—� 대í•� 현금 대ì‹� 급여ë¡� Agenus Inc. 보통ì£� 3,619주를 받았습니ë‹�. 해당 주ì‹ì€ 2025ë…� 8ì›� 22ì� 종가 $4.52ì—� 발행ë˜ì—ˆìœ¼ë©°, 회사ì� 개정ë� 2019ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� ë”°ë¼ ë°œí–‰ 시ì ì—� ì „ì•¡ 권리가 확정ë˜ì—ˆìŠµë‹ˆë‹�. ë³´ê³ ë� 발행 í›� 아멘 박사ëŠ� ì§ì ‘ 소유 270,930주와 ê·¸ì˜ IRA 계좌 ë°� 그가 수íƒìž� ë˜ëŠ” 파트너로 있는 기타 법ì¸ê³� ê´€ë ¨ëœ ê°„ì ‘ 보유 31,298ì£� ë°� 28,950주를 보유í•� 것으ë¡� 나타납니ë‹�.

Form 4ëŠ� 공개시장 매수ë‚� 매ë„ê°€ 아닌 ë‚´ë¶€ìž� 보수ì—� 대í•� 통ìƒì ì¸ ë³´ê³ ìž„ì„ ë°˜ì˜í•˜ë©°, 제출 서류ëŠ� 2025ë…� 8ì›� 25ì� 대리ì¸ì� 서명했습니다. 설명 ê°ì£¼ì—는 ì£¼ì‹ ë°œí–‰ì� Agenus ë³´ìƒìœ„ì›íšŒì˜ 승ì¸ì� 받았ê³� 명시ë� 급여 기간ì—� 대í•� 순급여를 대체한다는 ë‚´ìš©ì� 기재ë˜ì–´ 있습니다.

Garo H. Armen a reçu 3 619 actions ordinaires d'Agenus Inc. en rémunération en lieu et place d'un paiement en espèces pour la période de paie se terminant le 22 août 2025. Les actions ont été émises au cours de clôture de 4,52 $ le 22 août 2025 et sont entièrement acquises à l'émission conformément au plan d'incitation en actions modifié de 2019 de la société. Après l'émission déclarée, le Dr Armen apparaît comme bénéficiaire effectif de 270 930 actions en propriété directe, ainsi que de participations indirectes de 31 298 et 28 950 actions liées à ses comptes IRA et à d'autres entités où il exerce des fonctions de fiduciaire ou de partenaire.

Le formulaire Form 4 reflète un rapport de rémunération interne de routine plutôt qu'un achat ou une vente sur le marché ouvert ; le dépôt a été signé par un mandataire le 25 août 2025. Les notes explicatives indiquent que l'émission d'actions a été approuvée par le comité de rémunération d'Agenus et représente le salaire net pour la période de paie indiquée.

Garo H. Armen erhielt 3.619 Stammaktien der Agenus Inc. als Gehaltszahlung anstelle von Bargeld für den Abrechnungszeitraum, der am 22. August 2025 endete. Die Aktien wurden zum Schlusskurs von $4,52 am 22. August 2025 ausgegeben und sind gemäß dem geänderten Equity Incentive Plan von 2019 des Unternehmens bei Ausgabe vollständig unverfallbar. Nach der gemeldeten Zuteilung wird Dr. Armen als wirtschaftlicher Eigentümer von 270.930 Aktien direkt sowie von indirekten Beständen von 31.298 und 28.950 Aktien ausgewiesen, die mit seinen IRA-Konten und anderen Gesellschaften verbunden sind, bei denen er als Treuhänder oder Partner fungiert.

Das Formular Form 4 dokumentiert eine routinemäßige Insidervergütungsmeldung und keinen Kauf oder Verkauf am offenen Markt; die Einreichung wurde am 25. August 2025 von einem Bevollmächtigten unterzeichnet. Erläuternde Fußnoten geben an, dass die Aktienausgabe vom Vergütungsausschuss von Agenus genehmigt wurde und das Nettogehalt für den genannten Abrechnungszeitraum darstellt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ARMEN GARO H

(Last) (First) (Middle)
C/O AGENUS INC.
3 FORBES ROAD

(Street)
LEXINGTON MA 02421

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 08/22/2025 A 3,619 A $4.52(2) 270,930 D
Common Stock 31,298 I See footnote(3)
Common Stock 28,950 I See footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending August 22, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
2. $4.52 is the closing price of our Common Stock on August 22, 2025, the last trading day for the payroll date for the pay period ending August 22, 2025.
3. Shares are held in Dr. Armen's IRA accounts.
4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Remarks:
Chairman and Chief Executive Officer
/s/Christine M. Klaskin, as Attorney-in-Fact for Garo H. Armen 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Agenus

NASDAQ:AGEN

AGEN Rankings

AGEN Latest News

AGEN Latest SEC Filings

AGEN Stock Data

139.88M
31.33M
1.68%
30.1%
9.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON